ArticleRMD open2018
Haematopoietic stem cell transplantation in systemic sclerosis.
Article in RMD open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Preferential phosphodiesterase inhibition as a novel strategy to modulate key pathways in systemic sclerosis.Frontiers in immunology · 2026Review
- Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players.Journal of translational autoimmunity · 2025Review
- Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis.Frontiers in medicine · 2025Article
- Review
- Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.The Journal of dermatology · 2024Article
- Improving outcomes in scleroderma: recent progress of cell-based therapies.Rheumatology (Oxford, England) · 2023Review
- Patient Assessment Chronic Illness Care (PACIC) and its associations with quality of life among Swiss patients with systemic sclerosis: a mixed methods study.Orphanet journal of rare diseases · 2023Article
- Stem cell-based therapy for systemic sclerosis.Rheumatology advances in practice · 2023Review
- Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo.Bone marrow transplantation · 2022Article
- Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.Biomedicines · 2022Review
- Case Report: Chemotherapy-Associated Systemic Sclerosis: Is DNA Damage to Blame?Frontiers in medicine · 2022Article
- Calcineurin inhibitors in systemic sclerosis - a systematic literature review.Therapeutic advances in musculoskeletal disease · 2022Review
- Treatment for systemic sclerosis-associated interstitial lung disease.Current opinion in rheumatology · 2021Review
- Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications.Drugs in context · 2021Review
- Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.Expert opinion on emerging drugs · 2020Review
- Management of systemic sclerosis: the first five years.Current opinion in rheumatology · 2020Review
- Management of systemic sclerosis-associated interstitial lung disease in the current era.International journal of rheumatic diseases · 2020Article
- [Systemic sclerosis].Der Internist · 2019Review
- Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?International journal of molecular sciences · 2019Review
- [Systemic sclerosis-clinical picture, diagnosis, and treatment].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three randomised controlled trials of haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) demonstrated long-term survival benefits, induction of clinically meaningful, sustained improvement of forced vital capacity with improvements in skin thickening, vasculopathy and health-related quality of life, in contrast to a clinical decline in standard of care control groups. These benefits, however, must be weighed against the increased risk of transplant-related mortality. Further, with disease progression, severe extensive internal organ involvement and damage ensues, constituting an exclusion criterion for safety reasons, leaving a limited window whereby patients with SSc are eligible for HSCT. Although autologous HSCT offers the possibility of drug-free remission, relapse can occur, requiring re-initiation of disease modifying antirheumatic drugs. HSCT is also associated with secondary autoimmune diseases and gonadal failure. HSCT should be proposed for carefully selected patients with early rapidly progressive diffuse SSc whose clinical picture portends a poor prognosis for survival, but yet lacks advanced organ involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.